3M Innovative Properties Company

Karl J Manske

Philip D Heppner

George W Griesgraber

Tushar A Kshirsagar

Bryon A Merrill

Scott E Langer

Richard M Flynn

Kyle J Lindstrom

Michael J Rice

Gregory J Marszalek

Joshua R Wurst

Gregory D Lundquist, Jr

Sarah J Slania

Larry R Krepski

Suresh Iyer

Joseph F Dellaria, Jr

Shri Niwas

Daniel R Vitcak

John W Mickelson

Michael E Danielson

Erik D Olson

Ryan B Prince

Lian Soon Tan

Joan T Moseman

Kevin Jon Bechtold

Leslie J Charles

David A Hesselroth

Sarah C Slania

David A Hasselroth

Rama Vj Rajagopal

Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines

A polymeric coating for a glass substrate includes a hexafluoropropylene oxide derived silane polymer. The hexafluoropropylene oxide derived silane polymer has a molecular weight of greater than about 5500, a thickness of between about 2 and about 15 nanometers and a coefficient of friction constant of less than about 0.35. A water contact angle of the polymeric hexafluoropropylene oxide derived silane coating decreases by less than about 27% after being subjected to 10000 abrasion cycles.

Oleophobic coatings

A method of preferentially inducing IFN-&#x3b1; biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-&#x3b1; biosynthesis in an animal are disclosed.

Method of preferentially inducing the biosynthesis of interferon

Presently described is a composition comprising at least one first divalent unit comprising a pendant perfluoropolyether or perfluoroalkyl group; at least one second divalent unit comprising a pendant phosphorus-containing acid group; and at least one third unit comprising a terminal or pendant alkoxy silane group. Also described is a coating comprising the composition described herein dissolved or dispersed in a solvent and a method of providing a coated article or surface. Such method is particularly useful for providing corrosion protection to a metallic surface.

Fluorinated composition comprising phosphorus-containing acid group and alkoxy silane group

Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazoquinolines

[1,2]Imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and imidazo[4,5-c]pyridines) substituted with a fused ring containing an oxygen and/or nitrogen atom attached at the 1- and/or 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

[object Object]

1-Amino 1H-imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

1-Amino 1H-imidazoquinolines

Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and heterocyclyl or heteroaryl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

Heterocyclic ether substituted imidazoquinolines

Growing community of inventors

Roseville, MN, United States of America

Karl J Manske